BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in 鈥淓ye-Bulging鈥� Breast Cancer Patient
BriaCell Therapeutics (NASDAQ: BCTX) has reported significant progress in its Phase 2 study of Bria-IMT鈩� immunotherapy for advanced metastatic breast cancer. A patient who had previously failed 8 prior treatment regimens has shown remarkable results after 18+ months of treatment, including complete resolution of temporal lobe brain metastasis and continued reduction of orbital tumor that had caused eye bulging.
The patient has completed 29 treatment cycles over 21 months, with serial imaging at 8, 11, and 20 months confirming no detectable disease in the right temporal lobe and continued response in the orbital lesion. Tumor markers have remained significantly reduced from baseline, supporting the sustained radiologic response.
BriaCell Therapeutics (NASDAQ: BCTX) ha annunciato importanti progressi nello studio di Fase 2 della sua immunoterapia Bria-IMT鈩� per il carcinoma mammario metastatico avanzato. Un paziente, che aveva fallito 8 precedenti regimi terapeutici, ha mostrato risultati notevoli dopo pi霉 di 18 mesi di trattamento, inclusa la completa risoluzione della metastasi cerebrale al lobo temporale e la continua riduzione del tumore orbitale che causava protrusione oculare.
Il paziente ha completato 29 cicli di trattamento in un periodo di 21 mesi, con immagini seriali a 8, 11 e 20 mesi che hanno confermato l'assenza di malattia rilevabile nel lobo temporale destro e una risposta persistente nella lesione orbitale. I marcatori tumorali sono rimasti significativamente ridotti rispetto al basale, a sostegno della risposta radiologica duratura.
BriaCell Therapeutics (NASDAQ: BCTX) ha informado avances significativos en su estudio de Fase 2 de la inmunoterapia Bria-IMT鈩� para el c谩ncer de mama metast谩sico avanzado. Un paciente que hab铆a fallado en 8 reg铆menes de tratamiento previos ha mostrado resultados notables despu茅s de m谩s de 18 meses de tratamiento, incluyendo la resoluci贸n completa de la met谩stasis cerebral en el l贸bulo temporal y la reducci贸n continua del tumor orbital que causaba protrusi贸n ocular.
El paciente ha completado 29 ciclos de tratamiento durante 21 meses, con im谩genes seriadas a los 8, 11 y 20 meses que confirman la ausencia de enfermedad detectable en el l贸bulo temporal derecho y una respuesta continua en la lesi贸n orbital. Los marcadores tumorales se han mantenido significativamente reducidos respecto al inicio, respaldando la respuesta radiol贸gica sostenida.
BriaCell Therapeutics (NASDAQ: BCTX)電� 歆勴枆靹� 鞝勳澊靹� 鞙犽癌鞎旍棎 雽�頃� Bria-IMT鈩� 氅挫棴旃橂鞝滌潣 2靸� 鞛勳儊鞁滍棙鞐愳劀 欷戩殧頃� 歆勳爠鞚� 氤搓碃頄堨姷雼堧嫟. 鞚挫爠鞐� 8臧�歆� 旃橂 鞖旊矔鞐� 鞁ろ尐頃� 頇橃瀽臧� 18臧滌洈 鞚挫儊 旃橂 頉� 旄‰憪鞐� 雵� 鞝勳澊鞚� 鞕勳爠 靻岇嫟瓿� 鞎堦惮 霃岇稖鞚� 鞙犽皽頄堧崢 鞎堨檧 膦呾枒鞚� 歆�靻嶌爜 臧愳唽毳� 韽暔頃� 霙办柎雮� 瓴瓣臣毳� 氤挫榾鞀惦媹雼�.
鞚� 頇橃瀽電� 21臧滌洈 霃欖晥 29須� 旃橂 欤缄赴毳� 鞕勲頄堨溂氅�, 8, 11, 20臧滌洈 鞁滌爯鞚� 鞐办啀 鞓侅儊 瓴�靷棎靹� 鞖办浮 旄‰憪鞐届棎 臧愳 臧�電ロ暅 歆堧硲鞚� 鞐嗞碃 鞎堨檧 氤戨硛鞐愳劀 歆�靻嶌爜鞚� 氚橃潙鞚� 頇曥澑霅橃棃鞀惦媹雼�. 膦呾枒 響滌鞛愲姅 齑堦赴 雽�牍� 韥矊 臧愳唽頃橃棳 歆�靻嶌爜鞚� 鞓侅儊頃欖爜 氚橃潙鞚� 霋冯皼旃暕雼堧嫟.
BriaCell Therapeutics (NASDAQ : BCTX) a annonc茅 des progr猫s significatifs dans son 茅tude de phase 2 sur l'immunoth茅rapie Bria-IMT鈩� pour le cancer du sein m茅tastatique avanc茅. Un patient ayant 茅chou茅 脿 8 traitements ant茅rieurs a pr茅sent茅 des r茅sultats remarquables apr猫s plus de 18 mois de traitement, incluant la r茅solution compl猫te de la m茅tastase c茅r茅brale du lobe temporal et la r茅duction continue de la tumeur orbitale responsable d'une protrusion de l'艙il.
Le patient a termin茅 29 cycles de traitement sur une p茅riode de 21 mois, avec des imageries successives 脿 8, 11 et 20 mois confirmant l'absence de maladie d茅tectable dans le lobe temporal droit et une r茅ponse continue de la l茅sion orbitale. Les marqueurs tumoraux sont rest茅s significativement r茅duits par rapport au d茅part, soutenant la r茅ponse radiologique durable.
BriaCell Therapeutics (NASDAQ: BCTX) hat bedeutende Fortschritte in seiner Phase-2-Studie zur Bria-IMT鈩� Immuntherapie bei fortgeschrittenem metastasiertem Brustkrebs gemeldet. Ein Patient, der zuvor 8 vorherige Behandlungsregime nicht erfolgreich durchlaufen hatte, zeigt nach 眉产别谤 18 Monaten Behandlung bemerkenswerte Ergebnisse, darunter die vollst盲ndige R眉ckbildung der temporalen Hirnlappenmetastase und eine anhaltende Verringerung des orbit盲ren Tumors, der das Hervortreten des Auges verursacht hatte.
Der Patient hat 29 Behandlungszyklen 眉产别谤 21 Monate abgeschlossen, wobei serielle Bildgebungen nach 8, 11 und 20 Monaten best盲tigten, dass im rechten Temporallappen keine nachweisbare Erkrankung mehr vorliegt und die orbitale L盲sion weiterhin anspricht. Die Tumormarker blieben im Vergleich zum Ausgangswert deutlich reduziert, was die anhaltende radiologische Reaktion unterst眉tzt.
- None.
- Study still in Phase 2, requiring further validation
- Results based on single patient case study
Insights
BriaCell reports remarkable sustained tumor regression in a heavily pre-treated breast cancer patient, demonstrating potential clinical efficacy against brain metastases.
The updated results from BriaCell's Phase 2 study represent a significant clinical milestone. The patient's complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after more than 18 months of treatment is particularly noteworthy given the patient had previously failed 8 prior treatment regimens, including an antibody-drug conjugate (ADC) therapy.
Brain metastases present one of the most challenging treatment scenarios in breast cancer. Current therapeutic options for brain metastases are limited, with poor prognosis typically measured in months. The complete resolution of brain metastasis sustained for 18+ months without recurrence is therefore quite remarkable in this clinical context.
The orbital metastasis response is equally significant. Orbital metastases are rare (occurring in
The 29 treatment cycles completed over 21 months also indicate a manageable safety profile, essential for any maintenance therapy. The sustained reduction in tumor markers provides biochemical confirmation supporting the radiological findings.
This represents a single-patient case report from an ongoing Phase 2 trial, so broader efficacy conclusions require caution. However, durable responses in a patient with such treatment-refractory disease suggest Bria-IMT's immunotherapeutic approach may offer meaningful clinical benefit in a patient population with limited options and poor prognosis.
- [IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment
- 鈥淓ye bulging鈥� metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapy
- Patient remains on BriaCell鈥檚 Phase 2 study with 29 treatment cycles completed
PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (鈥淏riaCell鈥� or the 鈥淐ompany鈥�), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care today announced updated results from its ongoing Phase 2 study of Bria-IMT鈩� in combination with check point inhibitor in patients with advanced metastatic breast cancer (MBC).
BriaCell is pleased to report the sustained complete resolution of temporal lobe brain metastasis and continued orbital (behind the eye) tumor reduction after > 18 months of treatment in the Phase 2 study. The metastatic tumor initially caused proptosis 鈥揳 visibly bulging of the eye. As previously reported, the heavily pre-treated MBC patient had demonstrated a and a significant response in a right orbital metastasis at 8 months, then at 11 months. The patient has now maintained both responses for more than 18 months, with no evidence of brain tumor recurrence and ongoing tumor shrinkage in the orbital lesion.
Figure 1: Bria-IMT treatment resulted in complete resolution of the right temporal lobe lesion and continued regression of the right orbital (behind the eye) tumor. The right temporal lobe lesion is no longer detectable on the images taken at 8 months (May 2024), 11 months (Aug 2024), and 20 months (May 2025).
This patient had failed eight prior treatment regimens, including an antibody-drug conjugate (ADC), before initiating therapy with Bria-IMT plus checkpoint inhibition. She has now completed 29 treatment cycles and has been on BriaCell鈥檚 Phase 2 study for over 21 months. Serial imaging at 8, 11, and now 20 months have confirmed no detectable disease in the right temporal lobe, along with continued response in the orbital lesion. Additionally, the patient鈥檚 tumor markers have remained markedly reduced from baseline, further supporting the sustained radiologic response.
鈥淭hese encouraging results continue to suggest that our novel Bria-IMT regimen may provide durable immunotherapeutic benefit in late-stage breast cancer patients with brain metastases who have exhausted other options,鈥� stated Dr. William V. Williams, BriaCell鈥檚 President & CEO. 鈥淭he long-term response observed in this patient reinforces the potential of Bria-IMT to improve outcomes while maintaining a favorable tolerability profile.鈥�
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at .
Safe Harbor
This press release contains 鈥渇orward-looking statements鈥� that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥渁im,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell鈥檚 Bria-IMT regimen bringing relief to cancer patients whose medical needs remain unmet and the Bria-IMT regimen becoming a therapeutic option for metastatic breast cancer patients, are based on BriaCell鈥檚 current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 鈥淩isks and Uncertainties鈥� in the Company鈥檚 most recent Management鈥檚 Discussion and Analysis, under the heading 鈥淩isk Factors鈥� in the Company鈥檚 most recent Annual Information Form, and under 鈥淩isks and Uncertainties鈥� in the Company鈥檚 other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
Investor Relations Contact:
A photo accompanying this announcement is available at
FAQ
What are the latest clinical results for BriaCell's (BCTX) Bria-IMT treatment?
How long has the BCTX Phase 2 breast cancer patient been receiving treatment?
What type of cancer patients is BriaCell's (BCTX) Bria-IMT targeting?
How effective is BCTX's Bria-IMT in treating brain metastasis?
What was the patient's condition before starting BriaCell's treatment?
